A Study of ALKS 3831 in Adults With Schizophrenia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Bernard L. Silverman, MD
Alkermes, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
61 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Alkermes Investigational Site
Burgas, Bulgaria
- Alkermes Investigational Site
Kazanlak, Bulgaria
- Alkermes Investigational Site
Lovech, Bulgaria
- Alkermes Investigational Site
Novi Iskar, Bulgaria
- Alkermes Investigational Site
Pazardzhik, Bulgaria
- Alkermes Investigational Site
Sofia, Bulgaria
- Alkermes Investigational Site
Tserova Koria, Bulgaria
- Alkermes Investigational Site
Varna, Bulgaria
- Alkermes Investigational Site
Vratsa, Bulgaria
- Alkermes Investigational Site
Brno-mesto, Czechia
- Alkermes Investigational Site
Prague, Czechia
- Alkermes Investigational Site
Little Rock, Arkansas, United States
- Alkermes Investigational Site
Anaheim, California, United States
- Alkermes Investigational Site
Costa Mesa, California, United States
- Alkermes Investigational Site
Culver City, California, United States
- Alkermes Investigational Site
Escondido, California, United States
- Alkermes Investigational Site
Garden Grove, California, United States
- Alkermes Investigational Site
National City, California, United States
- Alkermes Investigational Site
Oakland, California, United States
- Alkermes Investigational Site
Oceanside, California, United States
- Alkermes Investigational Site
Orange, California, United States
- Alkermes Investigational Site
Pico Rivera, California, United States
- Alkermes Investigational Site
San Diego, California, United States
- Alkermes Investigational Site
Torrance, California, United States
- Alkermes Investigational Site
New Britain, Connecticut, United States
- Alkermes Investigational Site
Washington D.C., District of Columbia, United States
- Alkermes Investigational Site
Bradenton, Florida, United States
- Alkermes Investigational Site
Fort Lauderdale, Florida, United States
- Alkermes Investigational Site
Gainesville, Florida, United States
- Alkermes Investigational Site
Kissimmee, Florida, United States
- Alkermes Investigational Site
Leesburg, Florida, United States
- Alkermes Investigational Site
Oakland Park, Florida, United States
- Alkermes Investigational Site
Orlando, Florida, United States
- Alkermes Investigational Site
Atlanta, Georgia, United States
- Alkermes Investigational Site
Decatur, Georgia, United States
- Alkermes Investigational Site
Chicago, Illinois, United States
- Alkermes Investigational Site
Lake Charles, Louisiana, United States
- Alkermes Investigational Site
Shreveport, Louisiana, United States
- Alkermes Investigational Site
Rockville, Maryland, United States
- Alkermes Investigational Site
Flowood, Mississippi, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2013
- Primary completion
- 31 Dec 2014
- Completion
- 31 Mar 2015
- Last update posted
- 6 Oct 2021
- Registered enrollment
- 347
- Registry id
- NCT01903837
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.